TY - JOUR
T1 - COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest
T2 - The Lupus Midwest Network (LUMEN)
AU - Chevet, Baptiste
AU - Figueroa-Parra, Gabriel
AU - Yang, Jeffrey X.
AU - Hulshizer, Cassondra A.
AU - Gunderson, Tina M.
AU - Duong, Stephanie Q.
AU - Putman, Michael S.
AU - Barbour, Kamil E.
AU - Crowson, Cynthia S.
AU - Duarte-García, Alí
N1 - Publisher Copyright:
© 2022 The Journal of Rheumatology.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Objective. Patients with systemic lupus erythematosus (SLE) are at higher risk of poor outcomes from coronavirus disease 2019 (COVID-19). The vaccination rate among such patients is unknown. We aimed to assess COVID-19 vaccine uptake among patients with SLE. Methods. We included 342 patients with SLE from the Lupus Midwest Network (LUMEN) and 350 age-, sex-, race-, and county-matched comparators. Vaccination uptake for influenza, pneumococcal, and zoster vaccines before pandemic restrictions began (up to February 29, 2020) was assessed. First-dose COVID-19 vaccine uptake was electronically retrieved and manually ascertained (December 15, 2020, to July 31, 2021). Time to COVID-19 vaccination, demographics, SLE manifestations, medications, Charlson Comorbidity Index, Area Deprivation Index, and Rural-Urban Commuting Area codes were compared. Results. On July 31, 2021, 83.3% of patients with SLE and 85.5% of comparators were vaccinated against COVID-19. The COVID-19 vaccination rates were similar among SLE and comparators (hazard ratio 0.93, 95% CI 0.79-1.10). Unvaccinated patients with SLE were more likely than vaccinated patients to be men (27.3% vs 14.1%), younger (mean age 54.1 vs 58.8 yrs), have a shorter SLE duration (median 7.3 vs 10.7 yrs), and be less frequently vaccinated with influenza and pneumococcal vaccines. Conclusion. Patients with SLE in the Lupus Midwest Network had similar COVID-19 vaccination uptake as matched comparators, most of whom were vaccinated early when the vaccine became available. One in 6 patients with SLE remain unvaccinated.
AB - Objective. Patients with systemic lupus erythematosus (SLE) are at higher risk of poor outcomes from coronavirus disease 2019 (COVID-19). The vaccination rate among such patients is unknown. We aimed to assess COVID-19 vaccine uptake among patients with SLE. Methods. We included 342 patients with SLE from the Lupus Midwest Network (LUMEN) and 350 age-, sex-, race-, and county-matched comparators. Vaccination uptake for influenza, pneumococcal, and zoster vaccines before pandemic restrictions began (up to February 29, 2020) was assessed. First-dose COVID-19 vaccine uptake was electronically retrieved and manually ascertained (December 15, 2020, to July 31, 2021). Time to COVID-19 vaccination, demographics, SLE manifestations, medications, Charlson Comorbidity Index, Area Deprivation Index, and Rural-Urban Commuting Area codes were compared. Results. On July 31, 2021, 83.3% of patients with SLE and 85.5% of comparators were vaccinated against COVID-19. The COVID-19 vaccination rates were similar among SLE and comparators (hazard ratio 0.93, 95% CI 0.79-1.10). Unvaccinated patients with SLE were more likely than vaccinated patients to be men (27.3% vs 14.1%), younger (mean age 54.1 vs 58.8 yrs), have a shorter SLE duration (median 7.3 vs 10.7 yrs), and be less frequently vaccinated with influenza and pneumococcal vaccines. Conclusion. Patients with SLE in the Lupus Midwest Network had similar COVID-19 vaccination uptake as matched comparators, most of whom were vaccinated early when the vaccine became available. One in 6 patients with SLE remain unvaccinated.
KW - COVID-19
KW - hesitancy
KW - immunization
KW - systemic lupus erythematosus
KW - vaccination
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85140445225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140445225&partnerID=8YFLogxK
U2 - 10.3899/jrheum.220220
DO - 10.3899/jrheum.220220
M3 - Article
C2 - 35777817
AN - SCOPUS:85140445225
SN - 0315-162X
VL - 49
SP - 1276
EP - 1282
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 11
ER -